Allogene Therapeutics (ALLO) Set to Post Quarterly Earnings on Thursday

Allogene Therapeutics (NASDAQ:ALLO) will likely be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.1466) per share and revenue of $0.00 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.04. The company had revenue of $4.64 million during the quarter, compared to analyst estimates of $0.00 million. On average, analysts expect Allogene Therapeutics to post ($0.58) EPS for the current fiscal year and ($0.60) EPS for the next fiscal year.

Allogene Therapeutics Trading Up 5.7%

Shares of NASDAQ:ALLO opened at $1.30 on Thursday. The stock has a market capitalization of $449.14 million, a PE ratio of -1.94 and a beta of 0.56. The firm has a 50 day moving average of $1.66 and a 200-day moving average of $1.98. Allogene Therapeutics has a 12 month low of $1.04 and a 12 month high of $4.46.

Insider Activity

In other Allogene Therapeutics news, SVP Earl Douglas sold 29,697 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $2.12, for a total value of $62,957.64. Following the completion of the sale, the senior vice president owned 488,267 shares of the company’s stock, valued at approximately $1,035,126.04. This trade represents a 5.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Geoffrey Parker sold 36,342 shares of the business’s stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $1.34, for a total value of $48,698.28. Following the sale, the chief financial officer owned 1,045,877 shares of the company’s stock, valued at approximately $1,401,475.18. This represents a 3.36% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 13.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Weiss Ratings upgraded Allogene Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, October 21st. William Blair raised Allogene Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $6.00 price target on shares of Allogene Therapeutics in a research report on Monday, August 17th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.30.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” CAR T cell therapies for cancer. Unlike conventional autologous CAR T treatments, which are manufactured from an individual patient’s own cells, Allogene’s approach uses healthy donor cells that can potentially be produced in advance and administered more quickly.

The company’s investigational pipeline has included cemacabtagene ansegedleucel (cema-cel, formerly ALLO-501A) for certain patients with large B-cell lymphoma, as well as other allogeneic CAR T candidates being studied in blood cancers such as multiple myeloma and in solid tumors, including renal cell carcinoma.